News & Events

Nanopharm Limited & Sciarra Laboratories Inc

Announce Strategic Alliance

Nanopharm Announce Appointment of Head of Device Development

Device Development Established at Nanopharm Ltd

Nanopharm Announces Appointment of Chairman

Nanopharm Announces the Appointment of Mark Clement as Chairman of the Board

Addition of the Malvern G3-ID at Nanopharm

Demonstrating bioequivalence (BE) for complex generics such as nasal spray suspension drug products is a challenging task. Sponsors not only have to consider device requirements but also understand the properties of the API in the presence of functional excipients.

New research into in vitro strategies for demonstrating bioequivalence in generic nasal sprays

Nanopharm Ltd, supported by Malvern instruments and with funding from the Food and Drug Administration (FDA), have carried out experimental studies to identify analytical strategies that can help bring generic nasal sprays to market faster.

Nanopharm Ltd launches dissolution testing service for orally inhaled drug products utilising its proprietary UniDose™ technology

Nanopharm Ltd, a leading provider of tailored analytical and product development for orally inhaled and nasal drug products (OINDPs), today announced the availability of dissolution testing services utilising the company’s proprietary UniDose™ aerosol collection apparatus.

Nanopharm attended CPHI 2015, Madrid

Nanopharm attended CPHI 2015 in sunny Madrid. Great to meet up with new and existing clients.

New Web Site Launch